Dec 03, 2019 / 10:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Veracyte Conference Call. As a reminder, today's conference call is being recorded.
I'd now like to turn the conference over to Keith Kennedy, Veracyte's Chief Operating Officer and Chief Financial Officer. You may begin.
Keith S. Kennedy - Veracyte, Inc. - CFO, COO & Secretary
Thank you, Gigi. Good afternoon, everyone, and thanks for joining us to discuss Veracyte's exclusive global license of the NanoString nCounter platform for diagnostic use as well as the acquisition of the NanoString Prosigna breast cancer prognostic test and in-development LymphMark lymphoma subtyping assay. With me today is Bonnie Anderson, Veracyte's Chairman and Chief Executive Officer.
Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements include those regarding anticipated benefits of the transaction with NanoString, our future plans, prospects and
Veracyte, Inc. - Special Call Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers